Effect of dilazep dihydrochloride on urinary album in excretion in patients with autosomal dominant polycystic kidney disease

Nephron

Volumn 88, Issue 1, 2001, Pages 80-82

  Nakamura, Tsukasa ^a   Ushiyama, Chifuyu ^a   Takahashi, Yutaka ^b   Tanaka, Araki ^b   Shimada, Noriaki ^c   Ebihara, Isao ^c   Koide, Hikaru ^c  

^a Misato Junshin Hospital   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c KOTO HOSPITAL   (Japan)

Author keywords

Dilazep dihydrochloride; Extracellular matrix; Hypertension; Microalbuminuria; Polycystic kidney disease

Indexed keywords

ALBUMIN; CREATININE; DILAZEP; IMMUNOGLOBULIN A; NITROGEN; PLACEBO;

ADULT; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY POLYCYSTIC DISEASE; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL;

ALBUMINURIA; DILAZEP; FEMALE; HUMANS; HYPERTENSION, RENAL; MALE; MIDDLE AGED; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; VASODILATOR AGENTS;

EID: 0035012629     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000045963     Document Type: Article

References (17)

1. Freedman BI, Soucie JM, Chapman A, Krisher J, McClellan WM: Racial variation in autosomal dominant polycystic kidney disease. Am J Kidney Dis 2000;35:35-39.
2. Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, Jones RH: Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 1992;41:1311-1319.
3. Nagato S, Yamaguchi T, Kasahara M, Kusaka M, Matsuda T, Ogiso N, Takahasi H, Grantham JJ: Effect of probucol in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 2000;35:221-226.
4. Grantham JJ: Mechanisms of progression in autosomal dominant polycystic kidney disease. Kidney Int 1997;52(suppl 63):93-97.
5. Chapman AB, Johnson AM, Gabow PA, Schrier RW: Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994;5:1349-1354.
6. Deguchi H, Takeya H, Wada H, Gabazza EC, Hayashi N, Urano H, Suzuki K: Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes. Blood 1997;90:2345-2356.
7. Nakamura T, Ebihara I, Nagaoka I, Takahashi T, Tomino Y, Koide H: Abnormal regulation of insulin-like growth factor gene expression in peripheral blood mononuclcar cells from patients with IgA nephropathy. Am J Nephrol 1992;12:292-302.
8. Nakamura T, Ushiyama C, Shimada N, Sekizuka K, Ebihara I, Hara M, Koide H: Effect of the antiplatelet drug dilazep dihydrochloride on urinary podocytes in patients in the early stage of diabetic nephropathy. Diabetes Care 2000;23:1168-1171.
9. Giusti R, Neri M, Angelini D, Carlini A: Plasma concentration of endothelin and arterial pressure in patients with autosomal dominant polycystic kidney disease (abstract). 30th Congr EDTA-ERA, Glasgow 1993, p 110.
10. Polat H, Karayaylati I, Niyazova Z, Seyrek N, Paydas S, Sagliker Y: Hypertension, lipid abnormalities and cardiovascular changes in autosomal dominant polycystic kidney disease. Nephron 1998;78:369-371.
11. Ebihara I, Nakamura T, Shimada N, Koide H: Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis 1998;32:544-550.
12. Van Dijk MA, Peters DJM, Breuning MH, Chang PC: The angiotensin-converting enzyme genotype and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1999;10:1916-1920.
13. Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW: Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2000;35:427-432.
14. DeGaudio AR, Spina R, Di Filippo A, Feri M: Glomerular permeability and trauma. A correlation between microalbuminuria and injury severity score. Crit Care Med 1999;27:2105-2108.
15. Gohda T, Makita Y, Shike T, Funabiki K, Horikoshi S, Shirato I, Tomino Y: Effect of dilazep dihydrochloride, and antiplatelet agent, on the proliferation of cultured mouse glomerular mesangial cells. Nephron 2000;84:90-99.
16. Fick GM, Johnson AM, Hammond WS, Gabow PA: Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995;5:2048-2056.
17. Abbate M, Remuzzi G: Proteinuria as a mediator of tubulointerstitial injury. Kidney Blood Press Res 1999;22:37-46.